One80 Intermediaries Launches GeneBridge Gene Therapy Reinsurance Product
The solution mitigates the financial impact of high-cost gene therapy claims.
GeneBridge is a reinsurance facility designed for blocks of business including employer stop loss programs and health plans. Programs that purchase GeneBridge are reimbursed up to a scheduled amount for the list price and administration of the FDA-approved therapies.
More than 10,000 diseases are linked to genetic disorders fueling a rapid growth in approved treatments. At an average cost per therapy of over
“With the number of gene and cell therapies expected to double over the next two years, we saw a great need to mitigate the potentially catastrophic financial impact one or more of these claims would have on programs and employer groups,” said
The program will be administered through One80’s medical stop loss practice, a full-service Managing General Underwriter.
About
View source version on businesswire.com: https://www.businesswire.com/news/home/20240701143486/en/
Media Contact:
lmilne@one80intermediaries.com
(786) 865-4614
Source:


What is long-term care insurance, and why are premiums still rising?
This Week: Job openings, Fed meeting minutes, June nonfarm payrolls report
Advisor News
- Gen X and millennials seek new retirement model
- Are families ready for the costs of aging at home?
- When a client moves, their insurance plan needs to move, too
- A rising retirement challenge: The license to spend
- Financial stress leaves less room for retirement saving
More Advisor NewsAnnuity News
- Gen X and millennials seek new retirement model
- Global Atlantic names Dan Farrelly head of IMO and IBD channels
- A rising retirement challenge: The license to spend
- What lower interest rates mean to annuity payouts
- AM Best downgrades A-Cap insurers amid financial and regulatory troubles
More Annuity NewsHealth/Employee Benefits News
Life Insurance News